MedTrace Logo

A Study of RPL554 in Patients With Cystic Fibrosis

NCT02919995 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-05-21

Study results available
· View outcomes & findings →

Summary

This study evaluates two doses of RPL554 and placebo in adult patients with cystic fibrosis. All patients receive all three treatments in a randomised sequence.

Conditions

Interventions

DRUG

RPL554

RPL554 suspension administered using a nebuliser

DRUG

Placebo

Placebo solution administered using a nebuliser

Sponsors & Collaborators

  • Cystic Fibrosis Trust

    collaborator OTHER

  • Verona Pharma plc

    lead INDUSTRY

Principal Investigators

  • Andres Floto · Cambridge Centre for Medical Research, Papworth Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-08
Primary Completion
2017-11-03
Completion
2017-11-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02919995 on ClinicalTrials.gov